Senseonics announced today that it filed for CE mark for its Eversense 365 continuous glucose monitor (CGM) system.

Eversense 365 is the world’s first and only one year CGM, which was approved by the United States (US) Food and Drug Administration in September of 2024 and launched across the country in October of ...

Dexcom (Nasdaq:DXCM) announced today that it plans to establish a direct presence in Italy, bringing its CGM technology to ...

The use of a continuous glucose monitor during pregnancy may be more cost-effective than self-monitoring blood glucose for ...

In the Spring 2024 semester, Glucoguard was invited to participate in the MADO program through our ongoing relationship with ...

Aristotle Atlantic Partners, LLC, an investment advisor, released its “Focus Growth Strategy” fourth quarter 2024 investor ...

Glucose monitoring has evolved beyond its traditional role in diabetes management, with an increasing number of people using ...

New research suggests that wearing continuous glucose monitors could lower the risk of dementia. Experts discuss how symptoms can overlap between diabetes and dementia.

Shares of DexCom, Inc. (NASDAQ:DXCM – Get Free Report) have earned a consensus recommendation of “Moderate Buy” from the ...

Flagship Harbor Advisors LLC acquired a new stake in DexCom, Inc. (NASDAQ:DXCM – Free Report) during the 4th quarter, ...